BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 17337084)

  • 1. The survival outcomes of patients with resected non-small cell lung cancer differ according to EGFR mutations and the P21 expression.
    Na II; Rho JK; Choi YJ; Kim CH; Park JH; Koh JS; Ryoo BY; Yang SH; Lee JC
    Lung Cancer; 2007 Jul; 57(1):96-102. PubMed ID: 17337084
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer.
    Lee KH; Min HS; Han SW; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Kim YT; Kim TY; Heo DS; Bang YJ; Sung SW; Kim JH
    Lung Cancer; 2008 Jun; 60(3):401-7. PubMed ID: 18036700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor gene amplification in surgical resected Japanese lung cancer.
    Sasaki H; Shimizu S; Okuda K; Kawano O; Yukiue H; Yano M; Fujii Y
    Lung Cancer; 2009 Jun; 64(3):295-300. PubMed ID: 19058870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
    Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
    Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic implications of cell cycle-related proteins in primary resectable pathologic N2 nonsmall cell lung cancer.
    Mohamed S; Yasufuku K; Hiroshima K; Nakajima T; Yoshida S; Suzuki M; Sekine Y; Shibuya K; Iizasa T; Farouk A; Fujisawa T
    Cancer; 2007 Jun; 109(12):2506-14. PubMed ID: 17487846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients.
    Murray S; Timotheadou E; Linardou H; Vrettou AV; Kostopoulos I; Skrickova J; Papakostantinou C; Christodoulou C; Pectasides D; Samantas E; Papakostas P; Skarlos DV; Kosmidis P; Fountzilas G
    Lung Cancer; 2006 May; 52(2):225-33. PubMed ID: 16567021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications.
    Kosaka T; Yatabe Y; Endoh H; Kuwano H; Takahashi T; Mitsudomi T
    Cancer Res; 2004 Dec; 64(24):8919-23. PubMed ID: 15604253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.
    Brabender J; Danenberg KD; Metzger R; Schneider PM; Park J; Salonga D; Hölscher AH; Danenberg PV
    Clin Cancer Res; 2001 Jul; 7(7):1850-5. PubMed ID: 11448895
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of EGFR, HER2, TP53, and KRAS mutations of p14arf expression in non-small cell lung cancers in relation to smoking history.
    Mounawar M; Mukeria A; Le Calvez F; Hung RJ; Renard H; Cortot A; Bollart C; Zaridze D; Brennan P; Boffetta P; Brambilla E; Hainaut P
    Cancer Res; 2007 Jun; 67(12):5667-72. PubMed ID: 17575133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment.
    Marchetti A; Martella C; Felicioni L; Barassi F; Salvatore S; Chella A; Camplese PP; Iarussi T; Mucilli F; Mezzetti A; Cuccurullo F; Sacco R; Buttitta F
    J Clin Oncol; 2005 Feb; 23(4):857-65. PubMed ID: 15681531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidermal growth factor receptor (EGFR) mutation and p-EGFR expression in resected non-small cell lung cancer.
    McMillen E; Ye F; Li G; Wu Y; Yin G; Liu W
    Exp Lung Res; 2010 Nov; 36(9):531-7. PubMed ID: 20939760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.
    Rusch V; Klimstra D; Venkatraman E; Pisters PW; Langenfeld J; Dmitrovsky E
    Clin Cancer Res; 1997 Apr; 3(4):515-22. PubMed ID: 9815714
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase 9 and the epidermal growth factor signal pathway in operable non-small cell lung cancer.
    Cox G; Jones JL; O'Byrne KJ
    Clin Cancer Res; 2000 Jun; 6(6):2349-55. PubMed ID: 10873086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p21waf1/cip1 and transforming growth factor beta 1 protein expression correlate with survival in non-small cell lung cancer.
    Bennett WP; el-Deiry WS; Rush WL; Guinee DG; Freedman AN; Caporaso NE; Welsh JA; Jones RT; Borkowski A; Travis WD; Fleming MV; Trastek V; Pairolero PC; Tazelaar HD; Midthun D; Jett JR; Liotta LA; Harris CC
    Clin Cancer Res; 1998 Jun; 4(6):1499-506. PubMed ID: 9626468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
    Fukui T; Ohe Y; Tsuta K; Furuta K; Sakamoto H; Takano T; Nokihara H; Yamamoto N; Sekine I; Kunitoh H; Asamura H; Tsuchida T; Kaneko M; Kusumoto M; Yamamoto S; Yoshida T; Tamura T
    Clin Cancer Res; 2008 Aug; 14(15):4751-7. PubMed ID: 18676744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of EGFR mutation status on outcomes in patients with resected stage I non-small cell lung cancers.
    Izar B; Sequist L; Lee M; Muzikansky A; Heist R; Iafrate J; Dias-Santagata D; Mathisen D; Lanuti M
    Ann Thorac Surg; 2013 Sep; 96(3):962-8. PubMed ID: 23932319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.